Biocompatible Nanoparticles with Aggregation Induced Emission Characteristics as Fluorescent Bioprobes and Methods of Using the Same for in Vitro and in Vivo Imaging
Patent Information:
1. Filing Country: China
Application No: 201280042771.6
Filing Date: 03 March 2014
Patent No: ZL201280042771.6
Issue Date: 30 November 2016
2. Filing Country: Singapore
Application No: 11201400944Q
Filing Date: 25 March 2014
Patent No: 11201400944Q
Issue Date: 15 August 2016
3. Filing Country: USA
Application No: 14/342074
Filing Date: 28 February 2014
Patent No:
Issue Date:
4. Filing Country: China
Application No: 201610234837.1
Filing Date: 15 April 2016
Patent No:
Issue Date:
5. Filing Country: Singapore
Application No: 10201602988V
Filing Date: 15 April 2016
Patent No:
Issue Date:
 
Inventors:
Inventor 1: Prof. Benzhong, TANG
Inventor 2: Dr. Jianzhao, LIU
Inventor 3: Ms. Sijie, CHEN
Inventor 4: Prof. Jingzhi, SUN
Inventor 5: Prof. Anjun, QIN
Inventor 6: Mr. Wei, QIN
Inventor 7: Prof. Bin, LIU
Inventor 8: Mr. Kai, LI
Inventor 9: Mr. Dan, DING
Inventor 10: Prof. Qiuli, ZHAO

Technology
Novelty of the invention rests in the novel use of biocompatible nanoparticles with Aggregation-Induced Emission (AIE) characteristics as fluorescent bioprobes for cell imaging. Formulation of these red fluorescent emitters using biomacromolecule matrix yield uniformly sized nanoparticles (NPs) with high brightness and low cytotoxicity. These probes have been tested by using breast cancer cell and tumour bearing mice in in vivo experiment. When compared with the conventional cell imaging technology, competitive advantage of these probes lies in its ability to trace cell in a real time and non-invasive manner.
 
 
Potential Application   Advantage
This invention is fundamental. It opens up a new avenue for the development of AIE-active biocompatible NP-based probes for clinical cancer imaging. These probes can potentially be used for visualization of tumor for cancer diagnosis and therapeutics with high tissue penetration.   1) Excellent cancer cell uptake and prominent tumor targeting ability.
2) Excellent candidate materials for clinical cancer imaging and diagnostics.
     
Patent documents are available at [http://patentsearch2.ttc.ust.hk/ListPatents.asp], and can be viewed by inserting patent no., application no. or TTC code <TTC Code> into the corresponding field.
Contact information :
Ms Shirley Woo
(852) 2358 7918
cawoosw@ust.hk
HKUST R and D Corporation Ltd
http://rdc.ust.hk
(852) 2358 7917
ttcac@ust.hk
Technology Transfer Center
http://www.ttc.ust.hk/
   
香港九龍清水灣 香港科技大學
THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, CLEAR WATER BAY, KOWLOON